TY - JOUR
T1 - Research Priorities in Atrial Fibrillation Screening
T2 - A Report From a National Heart, Lung, and Blood Institute Virtual Workshop
AU - Benjamin, Emelia J.
AU - Go, Alan S.
AU - Desvigne-Nickens, Patrice
AU - Anderson, Christopher D.
AU - Casadei, Barbara
AU - Chen, Lin Y.
AU - Crijns, Harry J. G. M.
AU - Freedman, Ben
AU - Hills, Mellanie True
AU - Healey, Jeff S.
AU - Kamel, Hooman
AU - Kim, Dong-Yun
AU - Link, Mark S.
AU - Lopes, Renato D.
AU - Lubitz, Steven A.
AU - McManus, David D.
AU - Noseworthy, Peter A.
AU - Perez, Marco
AU - Piccini, Jonathan P.
AU - Schnabel, Renate B.
AU - Singer, Daniel E.
AU - Tieleman, Robert G.
AU - Turakhia, Mintu P.
AU - Van Gelder, Isabelle C.
AU - Cooper, Lawton S.
AU - Al-Khatib, Sana M.
PY - 2021/1/26
Y1 - 2021/1/26
N2 - Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected until complications such as stroke or heart failure occur. Hence, the public and clinicians have an intense interest in detecting AF earlier. However, the most appropriate strategies to detect undiagnosed AF (sometimes referred to as subclinical AF) and the prognostic and therapeutic implications of AF detected by screening are uncertain. Our report summarizes the National Heart, Lung, and Blood Institute's virtual workshop focused on identifying key research priorities related to AF screening. Global experts reviewed major knowledge gaps and identified critical research priorities in the following areas: (1) role of opportunistic screening; (2) AF as a risk factor, risk marker, or both; (3) relationship between AF burden detected with long-term monitoring and outcomes/treatments; (4) designs of potential randomized trials of systematic AF screening with clinically relevant outcomes; and (5) role of AF screening after ischemic stroke. Our report aims to inform and catalyze AF screening research that will advance innovative, resource-efficient, and clinically relevant studies in diverse populations to improve the diagnosis, management, and prognosis of patients with undiagnosed AF.
AB - Clinically recognized atrial fibrillation (AF) is associated with higher risk of complications, including ischemic stroke, cognitive decline, heart failure, myocardial infarction, and death. It is increasingly recognized that AF frequently is undetected until complications such as stroke or heart failure occur. Hence, the public and clinicians have an intense interest in detecting AF earlier. However, the most appropriate strategies to detect undiagnosed AF (sometimes referred to as subclinical AF) and the prognostic and therapeutic implications of AF detected by screening are uncertain. Our report summarizes the National Heart, Lung, and Blood Institute's virtual workshop focused on identifying key research priorities related to AF screening. Global experts reviewed major knowledge gaps and identified critical research priorities in the following areas: (1) role of opportunistic screening; (2) AF as a risk factor, risk marker, or both; (3) relationship between AF burden detected with long-term monitoring and outcomes/treatments; (4) designs of potential randomized trials of systematic AF screening with clinically relevant outcomes; and (5) role of AF screening after ischemic stroke. Our report aims to inform and catalyze AF screening research that will advance innovative, resource-efficient, and clinically relevant studies in diverse populations to improve the diagnosis, management, and prognosis of patients with undiagnosed AF.
KW - atrial fibrillation
KW - diagnostic screening programs
KW - prevention and control
KW - research
KW - stroke
KW - RHYTHM MONITORING STRATEGIES
KW - SOCIEDAD LATINOAMERICANA
KW - TRANSIENT ISCHEMIC ATTACK
KW - CRYPTOGENIC STROKE
KW - PRIMARY-CARE
KW - CARDIAC SOCIETY
KW - EHRA CONSENSUS DOCUMENT
KW - ORAL ANTICOAGULANTS
KW - AUSTRALIAN CLINICAL GUIDELINES
KW - COMPREHENSIVE EVALUATION
U2 - 10.1161/circulationaha.120.047633
DO - 10.1161/circulationaha.120.047633
M3 - Article
C2 - 33493033
SN - 0009-7322
VL - 143
SP - 372
EP - 388
JO - Circulation
JF - Circulation
IS - 4
ER -